TACROLIMUS IN THE TREATMENT OF DIFFERENT SKIN DISEASES


Cite item

Full Text

Abstract

Tacrolimus, a new calcineurin inhibitor, was used for topical therapy of skin diseases. Characteristics of the drug are presented, the mechanism of its action is described. The efficiency of tacrolimus is demonstrated by published data and the authors’ experiance. Tacrolimus was effective in the treatment of atopic dermatitis, its efficiency was comparable to that of topical corticosteroids. Tacrolimus was also effective in psoriasis, vitiligo, rosacea, and seborrheic dermatitis.

About the authors

O. Yu Olisova

I.M.Setchenov First Moscow Medical University

Therapeutic Faculty, Department of Dermatology and Venereology

N. G Kochergin

I.M.Setchenov First Moscow Medical University

Therapeutic Faculty, Department of Dermatology and Venereology

E. K Murakhovskaya

I.M.Setchenov First Moscow Medical University

Email: ekaterina_49@mail.ru
Therapeutic Faculty, Department of Dermatology and Venereology

G. M Keskin

I.M.Setchenov First Moscow Medical University

Therapeutic Faculty, Department of Dermatology and Venereology

A. O Olisov

Institute of Dermatology and Venereology

врач

M. I Davidovich

I.M.Setchenov First Moscow Medical University

Therapeutic Faculty, Department of Dermatology and Venereology

L. G Garanyan

I.M.Setchenov First Moscow Medical University

Therapeutic Faculty, Department of Dermatology and Venereology

V. A Shurubei

I.M.Setchenov First Moscow Medical University

Therapeutic Faculty, Department of Dermatology and Venereology

References

  1. Кочергин Н. Г., Черникова Е. А., Билалова У. Г. Атопический дерматит открытых участков и малассезиозная инфекция. Российский журнал кожных и венерических болезней. 2011; 2: 31 —3.
  2. Ruzichka T., Assmann T., Homey B. Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol. 1999; 135(5): 574—80.
  3. Lawrence I.D. Tacrolimus (FK506): experience in dermatology. Dermatol. Ther. 1998; 5: 74—84.
  4. Michel G., Kemeny L., Homey B., Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol. Today 1996; 17(3): 106—8.
  5. Gupta A.K., Adamiak A., Chow M. Tacrolimus: a review of its use for management of dermatoses. J. Eur. Acad. Dermatol. Venereol. 2002; 16(2): 100—14.
  6. Fleisher A.B.Jr. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroid therapy. J. Allergy Clin. Immunol. 1999; 104 (3, Pt 2): S126—30.
  7. Martin Ezquerra G., Sánchez Regaña M., Herrera Acosta E., Umbert Millet P.M. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J. Drugs Dermatol. 2006; 5(4): 334—6.
  8. Hanifin J.M., Paller A.S., Eichenfield L., Clark R.A., Korman N., Weinstein G., et al.; US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J. Am. Acad. Dermatol. 2005; 53 (2, Suppl. 2): S186—94.
  9. Sonthalia S., Singal A. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial. Int. J. Dermatol. 2012; 51(11): 1371—8. doi: 10.1111/j.1365-4632.2012.05459.x.
  10. Samycia M., Lin A.N. Efficacy of topical calcineurin inhibitors in lichen planus. J. Cutan. Med. Surg. 2012; 16(4): 221—9.
  11. Fortina A.B., Giulioni E., Tonin E. Topical tacrolimus in the treatment of lichen planus in a child. Pediatr. Dermatol. 2008; 25(5): 570—1. doi: 10.1111/j.1525-1470.2008.00736.x.
  12. Kathuria S., Khaitan B.K., Ramam M., Sharma V.K. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J. Dermatol. Venereol. Leprol. 2012; 78(1): 68—73. doi: 10.4103/0378-6323.90949.
  13. Silverberg J.I., Silverberg N.B. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. J. Drugs Dermatol. 2011; 10(5): 507—10.
  14. Garg G., Thami G.P. Clinical efficacy of tacrolimus in rosacea. J. Eur. Acad. Dermatol. Venereol. 2009; 23(2): 239—40. doi: 10.1111/j.1468-3083.2008.02822.x.
  15. Del Rosso J.Q. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002; 70(5): 271—5.
  16. Woo D.K., James W.D. Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005; 16(1): 6—21.
  17. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J. Am. Acad. Dermatol. 2001; 44(6): 995-8.
  18. Kuldeep C., Singhal H., Khare A.K., Mittal A., Gupta L.K., Garg A. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int. J. Trichology. 2011; 3(1): 20—4. doi: 10.4103/0974-7753.82123.
  19. Price V.H., Willey A., Chen B.K. Topical tacrolimus in alopecia areata. J. Am. Acad. Dermatol. 2005; 52(1): 138—9.
  20. Evans A.V. The expanding role of topical tacrolimus in dermatology. Clin. Exp. Dermatol. 2005; 30(2): 111—5.
  21. Lampropoulos C.E., Sangle S., Harrison P., Hughes G.R., D’Cruz D.P. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford). 2004; 43(11): 1383—5.
  22. Walker S.L., Kirby B., Chalmers R.J. Use of 0.1% tacrolimus ointment in patients with various forms of lupus erythematosus. Eur. J. Dermatol. 2002; 12(4): 387—9.
  23. Laino L., DiCarlo A. Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. Arch. Dermatol. 2011; 147(6): 760. doi: 10.1001/archdermatol.2011.120.
  24. Bohm M., Frieling U., Luger T.A., Bonsmann G. Successful treatment of anogenital lichen sclerosis with topical tacrolimus. Arch. Dermatol. 2003; 139(7): 922—4.
  25. Katsarou A., Armenaka M., Vosynioti V., Lagogianni E., Kalogeromitros D., Katsambas A. Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. J. Eur. Acad. Dermatol. Venereol. 2009; 23(4): 382—7.
  26. Rallis E., Economidi A., Verros C., Papadakis P. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J. Drugs Dermatol. 2006; 5(9): 906—7.
  27. Green C.M. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin. Exp. Dermatol. 2007; 32(4): 457—8.
  28. Simpson D., Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs. 2005; 65(6): 827—58.
  29. Reitamo S., Rustin M., Hatper J., Kalimo K., Rubins A., Cambazard F., et al.; 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. A 4-year follow-up study of atopic dermatitis therapy with 0,1% tacrolimus ointment in children and adult patients. Br. J. Dermatol. 2008; 159(4): 942—51. doi: 10.1111/j.1365-2133.2008.08747.x.
  30. Braza T.J., Dicarlo J.B., Soon S.L., McCal C.O. Tacrolimus 0,1 % ointment for seborrhoeic dermatitis: an open-label pilot study. Br. J. Dermatol. 2003; 148(6): 1242-44.
  31. Papp K.A., Papp A., Dahmer B., Clark C.S. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J. Am. Acad. Dermatol. 2012; 67(1): e11—5.
  32. Cook B.A., Warshaw E.M. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am. J. Clin. Dermatol. 2009; 10(2): 103—18.
  33. Rallis E., Korfitis C., Gregoriou S., Rigopoulos D. Assigning new roles to topical tacrolimus. Expert Opin. Investig. Drugs. 2007; 16(8): 1267—76.
  34. Mollison K. W., Fey T.A., Gauvin D.M., Kolano R.M., Sheets M.P., Smith M.L., et al. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. J. Invest. Dermatol. 1999; 112(5): 729—38.
  35. Kathuria S., Khaitan B.K., Ramam M., Sharma V.K. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J. Dermatol. Venereol. Leprol. 2012; 78(1): 68—73. doi: 10.4103/0378-6323.90949.
  36. Grimes P.E., Soriano T., Dytoc M.T. Topical tacrolimus for repigmentation of vitiligo. J. Am. Acad. Dermatol. 2002; 47(5): 789—91.
  37. Smith D.A., Tofte S.J., Hanifin J.M. Repigmentation of vitiligo with topical tacrolimus. Dermatology. 2002; 205(3): 301—3.
  38. Xu A.E., Zhang D.M., Wei X.D., Huang B., Lu L.J. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Int. J. Dermatol. 2009; 48(1): 86—90.
  39. Hartmann A., Brocker E.B., Hamm H. Occlusive treatment enhances efficacy of tactolimus 0,1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta Dermatol. Venerol. 2008; 88(5): 474—9. doi: 10.2340/00015555-0464.
  40. Chen G.Y., Hsu M.M., Tai H. K., Chou T.C., Tseng C.L., Chang H.Y., et al. Narrow-band UVB treatment of vitiligo in Chinese. J. Dermatol. 2005; 32(10): 793—800.
  41. Majid I. Does topical tacrolimus ointment enhance the efficacy of n arrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol. Photoimmunol. Photomed. 2010; 26(5): 230—4.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies